Abstract: The present invention relates to a method of diagnosing bacterial or fungal sepsis in a subject, which method comprises the step of measuring the level of TREM-1-Ligand or TREM-1-Ligand nucleic acid in a biological sample obtained from said subject. The method can involve contacting said biological sample with a compound capable of binding TREM-1-Ligand and detecting the level of TREM-1-Ligand present in the sample by observing the level of binding between said compound and TREM-1-Ligand. Compounds, compositions and kits for use in the diagnosis of bacterial or fungal sepsis are also provided.

Abstract: The present invention relates to a method of diagnosing bacterial or fungal sepsis in a subject, which method comprises the step of measuring the level of TREM-1-Ligand or TREM-1-Ligand nucleic acid in a biological sample obtained from said subject. The method can involve contacting said biological sample with a compound capable of binding TREM-1-Ligand and detecting the level of TREM-1-Ligand present in the sample by observing the level of binding between said compound and TREM-1-Ligand. Compounds, compositions and kits for use in the diagnosis of bacterial or fungal sepsis are also provided.

Abstract: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

Abstract: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

Abstract: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

Abstract: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

Abstract: The present invention relates to novel retinoid antagonists of the formula I wherein the dotted bond can be either hydrogenated or form a double bond; and, when the dotted bond forms a double bond, R1 is lower alkyl and R2 is hydrogen; and, when the dotted bond is hydrogenated, R1 and R2 taken together are methylene to form a cis-substituted cyclopropyl ring; R3 is hydroxy or lower alkoxy; R4 is alkyl or alkoxy; and R5 and R6 are, independently, a C4-12 alkyl or a 5-12 cycloalkyl substituent containing from 1-3 rings which are either unsubstituted or substituted with from 1-3 lower alkyl groups, with the carbon atom of R5 and R6 being linked to the remainder of the molecule to form a quaternary carbon atom pharmaceutically acceptable salts of carbocylic acids of the formula I; as well as method for the treatment of osteoporosis and preneoplastic and neoplastic diseases, and a method for reducing or abolishing adverse events in subjects receiving retinoid agonist treatment by administering a

Abstract: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

Abstract: The present invention relates to the use of a peptide from the circumsporozoite (CS) protein of Plasmodium falciparum (P. falciparum) and the derivatives thereof as a universally recognized T-cell epitope i.e. an epitope which is recognized in association with many different human and mouse major histocompatibility complex (MHC) haplotypes e.g. in the context of the human MHC class II molecules such as DR1, DR2, DR4, DR5, DRw6, DR7 or DR9. Furthermore the present invention relates to the above-mentioned peptide per se and to immunogenic compositions comprising such a peptide or a derivative thereof. These immunogenic compositions can be used as vaccines to elicit a durable immune response against a pathogenic agent in humans and animals irrespective of the MHC haplotype of the host.